Teva Pharmaceutical Industries announced Tuesday morning that the U.S. District Court for the Southern District of New York denied a motion for summary judgment, filed by Sandoz Inc./Momenta Pharmaceuticals Inc., that the patents at issue are invalid for indefiniteness.
Teva Pharmaceutical broke out sharply to the upside around mid-morning Tuesday and finished higher by 1.34 at $53.12 on above average volume. The stock has been climbing for the past week and set a month and a half high.
No comments:
Post a Comment